<DOC>
	<DOCNO>NCT00252876</DOCNO>
	<brief_summary>This 107-week open-label , multi-center long-term extension study GALLANT study 2/22 , 5 , 7 , 8 14 monitor safety tolerability oral tesaglitazar 1 mg patient type 2 diabetes 104 week treatment . The total duration , include treatment follow-up , 107 week .</brief_summary>
	<brief_title>GALLEX 1 - Long Term Extension Study Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Provision write informed consent Men woman &gt; =18 year age Female patient : postmenopausal , hysterectomized , childbearing potential , use reliable method birth control Completed last two visit randomize treatment period GALLANT 2/22 , 5 , 7 , 8 14 study . Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level twice normal range Creatine kinase 3 time upper limit normal Previous enrollment longterm extension study Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>